Preparation and storage of liposomal RNA formulations suitable for therapy
The present disclosure relates to methods for preparing RNA lipoplex particles for delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods which allow preparing RNA lipoplex particles in an industrial GMP-compliant manner. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of the product quality and, in particular, without substantial loss of RNA activity.
1. A composition comprising:
RNA lipoplex particles comprising:
RNA, and
at least one cationic lipid and at least one additional lipid,
sodium chloride at a concentration of about 10 mM or less,
a stabilizer at a concentration of about 10% weight by volume percent (% w/v) or less, and a buffer.
2. The composition of claim 1 , wherein the sodium chloride is at a concentration from about 5 mM to about 10 mM.
3. The composition of claim 1 , wherein the composition has an osmolality from about 200 mOsmol/kg to about 450 mOsmol/kg.
4. The composition of claim 1 , wherein the concentration of stabilizer in the composition is from about 5 to about 10% (w/v).
5. The composition of claim 1 , wherein the stabilizer is a carbohydrate selected from a monosaccharide, a disaccharide, a trisaccharide, a sugar alcohol, an oligosaccharide or its corresponding sugar alcohol, and a straight chain polyalcohol.
6. The composition of claim 1 , wherein the stabilizer is sucrose or trehalose.
7. The composition of claim 1 , wherein the stabilizer is sucrose or trehalose at a concentration from about 5 to about 10% (w/v).
8. The composition of claim 1 , wherein the buffer is selected from the group consisting of 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), histidine, acetic acid/sodium acetate, and MES (2-(N-morpholino)ethanesulfonic acid).
9. The composition of claim 1 , wherein the composition has a pH from 6.0 to 7.2, 6.0 to 7.0, from 6.2 to 7.0, from 6.5 to 7.0, or from 6.5 to 6.7.
10. The composition of claim 1 , wherein the buffer is present at a concentration from 2.5 mM to 10 mM.
11. The composition of claim 1 , wherein the buffer is HEPES at a concentration of about 7.5 mM or less with a pH of about 6.5 or about 6.7.
12. The composition of claim 1 , wherein the at least one cationic lipid comprises 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) and/or 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP).
13. The composition of claim 1 , wherein the at least one additional lipid comprises 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE), cholesterol (Chol) and/or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).
14. The composition of claim 1 , wherein the at least one cationic lipid comprises 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) and the at least one additional lipid comprises 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE).
15. The composition of claim 1 , wherein the molar ratio of the at least one cationic lipid to the at least one additional lipid is from about 4:1 to about 1:2.
16. The composition of claim 1 , wherein the RNA lipoplex particles comprise DOTMA and DOPE in a molar ratio of from about 4:1 to 1:2.
17. The composition of claim 1 , wherein the composition further comprises a chelating agent.
18. The composition of claim 17 , wherein the chelating agent is ethylenediaminetetraacetic acid (EDTA).
19. The composition of claim 1 , wherein the RNA encodes a peptide or protein comprising at least one epitope, wherein the ratio of positive charges to negative charges in the composition is from about 1:2 to about 1.9:2, or about 1.3:2.0.
20. A composition comprising:
RNA lipoplex particles comprising:
RNA encoding a peptide or protein comprising at least one epitope,
DOTMA and DOPE in a molar ratio of about 2:1,
wherein the ratio of positive charges to negative charges in the composition is about 1.3:2.0,
sodium chloride at a concentration of about 7.5 mM,
sucrose at a concentration of about 10% (w/v),
HEPES at a concentration of about 7.5 mM with a pH of about 6.5 or about 6.7, and
EDTA at a concentration of about 2.5 mM.
21. The composition of claim 1 , wherein the RNA lipoplex particles have an average diameter that ranges from about 200 to about 800 nm, from about 250 to about 700 nm, from about 400 to about 600 nm, from about 300 nm to about 500 nm, or from about 350 nm to about 400 nm.
22. The composition of claim 1 , wherein the amount of RNA in the composition is from about 0.01 mg/mL to about 1 mg/mL, about 0.05 mg/mL to about 0.5 mg/mL, about 0.05 mg/mL, or about 0.02 mg/mL.
23. The composition of claim 1 , further comprising an adjuvant.
24. The composition of claim 1 , wherein the composition is in a liquid, frozen or dehydrated state.
25. The frozen composition of claim 24 , wherein the composition is stable at a temperature of about −15° C. for at least one month.
26. The composition of claim 24 , which is an aqueous composition and can be administered directly to a subject.
27. The composition of claim 1 , which is formulated for systemic administration.
28. A method of preparing a liquid composition for direct administration to a subject comprising RNA lipoplex particles comprising (i) thawing the frozen composition of claim 24 or (ii) dissolving the dehydrated composition of claim 24 .
29. The composition of claim 1 , wherein the molar ratio of the at least one cationic lipid to the at least one additional lipid is about 2:1.
30. The composition of claim 1 , wherein the RNA lipoplex particles comprise DOTMA and DOPE in a molar ratio of about 2:1.
31. The composition of claim 1 , wherein the sodium chloride concentration is from about 5 mM to about 7.5 mM.
32. The composition of claim 6 , wherein the sodium chloride concentration is from about 5 mM to about 7.5 mM.
33. The composition of claim 7 , wherein the sodium chloride concentration is from about 5 mM to about 7.5 mM.
34. The composition of claim 1 , wherein the composition is stable for at least one month when stored in a frozen state at a temperature of about −15° C.
35. The composition of claim 34 , wherein stability is assessed by particle size, polydispersity, or RNA integrity.
36. The composition of claim 1 , wherein the composition is stable for at least one week when stored in a liquid state at a temperature of about 25° C.
37. The composition of claim 36 , wherein stability is assessed by particle size, polydispersity, or RNA integrity.